{"id":9617,"date":"2021-01-18T11:49:23","date_gmt":"2021-01-18T19:49:23","guid":{"rendered":"https:\/\/todaysveterinarybusiness.com\/?p=9617"},"modified":"2022-06-15T17:46:45","modified_gmt":"2022-06-15T17:46:45","slug":"fda-epilepsy-lymphoma-drugs-dogs","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/","title":{"rendered":"FDA Endorses Canine Epilepsy and Lymphoma Drugs"},"content":{"rendered":"

Two new oral medications \u2014 one for the control of seizures in dogs with idiopathic epilepsy and the other for the treatment of canine lymphoma \u2014 have received conditional approval from the U.S. Food and Drug Administration.<\/p>\n

The epilepsy drug, KBroVet-CA1 (potassium bromide chewable tablets), was developed by Pegasus Laboratories Inc., a contract manufacturer and the maker of the PRN Pharmacal brand of veterinary medications.<\/p>\n

Given daily, KBroVet-CA1 will be available by prescription only. The active ingredient, potassium bromide, is a halide salt, according to a Freedom of Information Summary, \u201cand when the salt passes through neuronal channels, it hyperpolarizes neuronal membranes and stabilizes the neurons. This reduces the likelihood of a seizure<\/a>.\u201d<\/p>\n

Pegasus is headquartered in Pensacola, Florida.<\/p>\n

Meanwhile, Anivive Lifesciences Inc. of Long Beach, California, earned the go-ahead for Laverdia-CA1 (verdinexor tablets), which the FDA described as the first conditionally approved oral treatment for dogs with lymphoma<\/a>. An injectable lymphoma drug, VetDC\u2019s Tanovea-CA1, was similarly approved in 2016.<\/p>\n

Laverdia-CA1 should be administered twice a week, according to the FDA. The medication is expected to hit the veterinary market this spring, Anivive reported on its website.<\/p>\n

\u201cLymphoma is a devastating cancer in dogs, with few FDA-approved treatments available,\u201d said Steven M. Solomon, DVM, MPH, director of the FDA\u2019s Center for Veterinary Medicine.<\/p>\n

The conditional approvals followed a move by Congress in 2018 to expand opportunities for veterinary drug developers.<\/p>\n

\u201cConditional approval allows veterinarians to access needed treatments while the drug company collects additional effectiveness data, such as through trials with client-owned dogs,\u201d the FDA noted. \u201cThe company then has up to five years to complete effectiveness studies to support a full approval.\u201d<\/p>\n

\n

Did you know a subscription to Today\u2019s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here<\/a> (and renew each year). You also can sign up to receive the Today\u2019s Veterinary Business weekly e-newsletter.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Medications from Pegasus Laboratories and Anivive Lifesciences earned conditional approvals.<\/p>\n","protected":false},"author":45,"featured_media":9618,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":0,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-9617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-online","column-news","clinical_topics-news","clinical_topics-veterinary-products"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"\nFDA Endorses Canine Epilepsy and Lymphoma Drugs | Today's Veterinary Business<\/title>\n<meta name=\"description\" content=\"Oral medications for the control of seizures in dogs with idiopathic epilepsy and the treatment of canine lymphoma won conditional approval.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Endorses Canine Epilepsy and Lymphoma Drugs\" \/>\n<meta property=\"og:description\" content=\"Oral medications for the control of seizures in dogs with idiopathic epilepsy and the treatment of canine lymphoma won conditional approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/\" \/>\n<meta property=\"og:site_name\" content=\"Today's Veterinary Business\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/todaysveterinarybusiness\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-18T19:49:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-15T17:46:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2021\/01\/Drug-Chemistry.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"544\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Louise S. Dunn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@tvbpublication\" \/>\n<meta name=\"twitter:site\" content=\"@tvbpublication\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Louise S. Dunn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/\"},\"author\":{\"name\":\"Louise S. Dunn\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/person\\\/06c2358bd95d11022006429d3cfecbeb\"},\"headline\":\"FDA Endorses Canine Epilepsy and Lymphoma Drugs\",\"datePublished\":\"2021-01-18T19:49:23+00:00\",\"dateModified\":\"2022-06-15T17:46:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/01\\\/Drug-Chemistry.jpg\",\"articleSection\":[\"Online\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/\",\"name\":\"FDA Endorses Canine Epilepsy and Lymphoma Drugs | Today's Veterinary Business\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/01\\\/Drug-Chemistry.jpg\",\"datePublished\":\"2021-01-18T19:49:23+00:00\",\"dateModified\":\"2022-06-15T17:46:45+00:00\",\"description\":\"Oral medications for the control of seizures in dogs with idiopathic epilepsy and the treatment of canine lymphoma won conditional approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/01\\\/Drug-Chemistry.jpg\",\"contentUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/01\\\/Drug-Chemistry.jpg\",\"width\":1024,\"height\":544,\"caption\":\"new drugs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/fda-epilepsy-lymphoma-drugs-dogs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Endorses Canine Epilepsy and Lymphoma Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#website\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\",\"name\":\"Today's Veterinary Business\",\"description\":\"Veterinary Business Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\",\"name\":\"Today's Veterinary Business\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/02\\\/tvb-logo.png\",\"contentUrl\":\"https:\\\/\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/02\\\/tvb-logo.png\",\"width\":258,\"height\":71,\"caption\":\"Today's Veterinary Business\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/todaysveterinarybusiness\",\"https:\\\/\\\/x.com\\\/tvbpublication\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/todaysveterinarybusiness\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/person\\\/06c2358bd95d11022006429d3cfecbeb\",\"name\":\"Louise S. Dunn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"caption\":\"Louise S. Dunn\"},\"sameAs\":[\"http:\\\/\\\/www.tvb.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Endorses Canine Epilepsy and Lymphoma Drugs | Today's Veterinary Business","description":"Oral medications for the control of seizures in dogs with idiopathic epilepsy and the treatment of canine lymphoma won conditional approval.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"FDA Endorses Canine Epilepsy and Lymphoma Drugs","og_description":"Oral medications for the control of seizures in dogs with idiopathic epilepsy and the treatment of canine lymphoma won conditional approval.","og_url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/","og_site_name":"Today's Veterinary Business","article_publisher":"https:\/\/www.facebook.com\/todaysveterinarybusiness","article_published_time":"2021-01-18T19:49:23+00:00","article_modified_time":"2022-06-15T17:46:45+00:00","og_image":[{"width":1024,"height":544,"url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2021\/01\/Drug-Chemistry.jpg","type":"image\/jpeg"}],"author":"Louise S. Dunn","twitter_card":"summary_large_image","twitter_creator":"@tvbpublication","twitter_site":"@tvbpublication","twitter_misc":{"Written by":"Louise S. Dunn","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#article","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/"},"author":{"name":"Louise S. Dunn","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/person\/06c2358bd95d11022006429d3cfecbeb"},"headline":"FDA Endorses Canine Epilepsy and Lymphoma Drugs","datePublished":"2021-01-18T19:49:23+00:00","dateModified":"2022-06-15T17:46:45+00:00","mainEntityOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2021\/01\/Drug-Chemistry.jpg","articleSection":["Online"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/","name":"FDA Endorses Canine Epilepsy and Lymphoma Drugs | Today's Veterinary Business","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#primaryimage"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2021\/01\/Drug-Chemistry.jpg","datePublished":"2021-01-18T19:49:23+00:00","dateModified":"2022-06-15T17:46:45+00:00","description":"Oral medications for the control of seizures in dogs with idiopathic epilepsy and the treatment of canine lymphoma won conditional approval.","breadcrumb":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#primaryimage","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2021\/01\/Drug-Chemistry.jpg","contentUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2021\/01\/Drug-Chemistry.jpg","width":1024,"height":544,"caption":"new drugs"},{"@type":"BreadcrumbList","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-epilepsy-lymphoma-drugs-dogs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/"},{"@type":"ListItem","position":2,"name":"FDA Endorses Canine Epilepsy and Lymphoma Drugs"}]},{"@type":"WebSite","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#website","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/","name":"Today's Veterinary Business","description":"Veterinary Business Magazine","publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization","name":"Today's Veterinary Business","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/logo\/image\/","url":"https:\/\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2022\/02\/tvb-logo.png","contentUrl":"https:\/\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2022\/02\/tvb-logo.png","width":258,"height":71,"caption":"Today's Veterinary Business"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/todaysveterinarybusiness","https:\/\/x.com\/tvbpublication","https:\/\/www.linkedin.com\/company\/todaysveterinarybusiness"]},{"@type":"Person","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/person\/06c2358bd95d11022006429d3cfecbeb","name":"Louise S. Dunn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","caption":"Louise S. Dunn"},"sameAs":["http:\/\/www.tvb.com"]}]}},"_links":{"self":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/comments?post=9617"}],"version-history":[{"count":2,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9617\/revisions"}],"predecessor-version":[{"id":18557,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9617\/revisions\/18557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/media\/9618"}],"wp:attachment":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/media?parent=9617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/categories?post=9617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/tags?post=9617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}